Nadire Özenver1, Dinesh Chandra Agrawal2*

1 Department of Pharmacognosy, Faculty of Pharmacy, Hacettepe University 06100 Ankara, Turkey

2 Department of Applied Chemistry, Chaoyang University of Technology, Taichung City 413310, Taiwan

 

Download Citation: |
Download PDF


ABSTRACT

Cannabis or marijuana (Cannabis sativa) contains more than one hundred chemical compounds. Of these, tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most common chemicals. THC is the chemical that gives a “high” and has various psychoactive characteristics. Cannabidiol, on the other hand, has no intoxicating qualities yet provides all the medical benefits, such as relief from anxiety, depression, insomnia, cancer, neuropathic pain, epilepsy, acute respiratory distress syndrome, Parkinson’s disease, Alzheimer’s disease, etc. In the present article, CBD oil extraction techniques, the mechanism of action of cannabinoids, and the role of CBD in relief from pain, anxiety, depression, and epilepsy have been reviewed.


Keywords: Anxiety, Cannabidiol (CBD), Depression, Epilepsy, Tetrahydrocannabinol (THC), Pain.


Share this article with your colleagues

 


REFERENCES

  1. Abame, M.A., He, Y., Wu, S., Xie, Z., Zhang, J., Gong, X., Wu, C., Shen, J. 2021. Chronic administration of synthetic cannabidiol induces antidepressant effects involving modulation of serotonin and noradrenaline levels in the hippocampus. Neuroscience Letters, 744, 135594.

  2. Ahrens, J., Demir, R., Leuwer, M., Roche, J., Krampfl, K., Foadi, N., Karst, M., Haeseler, G. 2009. The non-psychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-beta glycine receptor functions. Pharmacology, 83, 217–222.

  3. Anonymous. 2022. Retrieved 2022-08-19 from https:// pharmstrong.com/what-are-the-most-popular-cbd-extraction-methods/.

  4. Argueta, D.A., Ventura, C.M., Kiven, S., Sagi, V. Gupta, K. 2020. A balanced approach for cannabidiol use in chronic pain. Frontiers in Pharmacology, 11, 561.

  5. Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H.N., de Oliveira, D.C.G., De Martinis, B.S., Kapczinski, F., Quevedo J., Roesler R., Schröder N., Nardi A.E., Martín-Santos, R., Hallak, J.E.C., Zuardi A.W., Crippa, J.A. 2011. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36, 1219–1226.

  6. Bioscience, Greenwich. 2018. Epidiolex® (Cannabidiol). Retrieved 2022-01-24 from https://www.greenwichbio sciences.com/epidiolex.

  7. Blake, D.R., Robson, P., Ho, M., Jubb, R. W., McCabe, C.S. 2006. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology, 45, 50–52.

  8. Bonini, S.A., Premoli, M., Tambaro, S., Kumar, A., Maccarinelli, G., Memo, M., Mastinu, A. 2018. Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history. Journal of Ethnopharmacology, 227, 300–315.

  9. Chaturvedi, R.K., Agrawal, D.C. 2021. Cannabis-induced neuroactivity: research trends and commercial prospects. Medicinal Herbs and Fungi, 159–185.

  10. Cuñetti, L., Manzo, L., Peyraube, R., Arnaiz, J., Curi, L., Orihuela S. 2018. Chronic pain treatment with cannabidiol in kidney transplant patients in Uruguay. Transplant Proceedings, 50, 461–464.

  11. Cunha, J.M., Carlini, E.A., Pereira, A.E., Ramos, O.L., Pimentel, C., Gagliardi, R., Sanvito, W.L., Lander, N., Mechoulam, R. 1980. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology, 21, 175–185.

  12. de Mello Schier, A.R., de Oliveira Ribeiro, N.P., Coutinho, D.S., Machado, S., Arias-Carrión, O., Crippa, J.A., Zuardi, A.W., Nardi, A.E., Silva, A.C. 2014. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurological Disorders Drug Targets, 13, 953–960.

  13. Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., Wong, M., Tilton, N., Bruno, P., Bluvstein, J., Hedlund, J., Kamens R., Maclean, J., Nangia, S., Singhal, N.S., Wilson, C.A., Patel, A., Cilio, M.R. 2016. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurology, 15, 270–278.

  14. Food and Drug Administration (FDA) 2022. What you should know about using cannabis, including CBD, when pregnant or breastfeeding. Retrieved 2022-08-18 from https://www.fda.gov/consumers/consumer-updates/what -you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding.

  15. Florensa-Zanuy, E., Garro-Martínez, E., Adell, A., Castro, E., Díaz, A., Pazos, A., Mac-Dowell, K.S., Martín-Hernández, D., Pilar-Cuéllar, F. 2021. Cannabidiol antidepressant-like effect in the lipopolysaccharide model in mice: modulation of inflammatory pathways. Biochemical Pharmacology, 185, 114433.

  16. Franco, V., Bialer, M., Perucca, E. 2021. Cannabidiol in the treatment of epilepsy: current evidence and perspectives for further research. Neuropharmacology, 185, 108442.

  17. García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., Manzanares, J. 2020. Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules, 10, 1575.

  18. Gaoni, Y., Mechoulam, R. 1964. Isolation, structure, and partial synthesis of an active constituent of Hashish. Journal of American Chemical Society, 86, 1646–1647.

  19. Grand View Research. 2021. Cannabidiol market growth analysis report 2021-2028. https://www.grandview research.com/industry-analysis/cannabidiol-cbd-market.

  20. Gray, R.A., Whalley, B.J. 2020. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disorders, 22 (S1), 10–15.

  21. Guerrero-Alba, R., Barragán-Iglesias, P., González-Hernández, A., Valdez-Moráles, E.E., Granados-Soto, V., Condés-Lara, M., Rodríguez, M.G., Marichal-Cancino, B.A. 2019. Some prospective alternatives for treating pain: the endocannabinoid system and its putative receptors GPR18 and GPR55. Frontiers in Pharmacology, 9, 1496.

  22. Gusho, C.A., Court, T. 2020. Cannabidiol: a brief review of its therapeutic and pharmacologic efficacy in the management of joint disease. Cureus, 12, e7375.

  23. Hammell, D.C., Zhang, L.P., Ma, F., Abshire, S.M., McIlwrath, S.L., Stinchcomb, A.L., Westlund, K.N. 2016. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. European Journal of Pain, 20, 936–948.

  24. Hanuš, L.O., Meyer, S.M., Muñoz, E., Taglialatela-Scafati, O., Appendino, G. 2016. Phytocannabinoids: a unified critical inventory. Natural Product Reports, 33, 1357–1392.

  25. Healthline 2022. Retrieved 2022-08-19 from https://www. healthline.com/reviews/cbd-products.

  26. Hundal, H., Lister, R., Evans, N., Antley, A., Englund, A., Murray, R.M., Freeman, D., Morrison, P.D. 2018. The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. Journal of Psychopharmacology, 32, 276–282.

  27. Ibeas Bih, C., Chen, T., Nunn, A.W., Bazelot, M., Dallas, M., Whalley, B.J. 2015. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 12, 699–730.

  28. Izquierdo, I., Orsingher, O.A., Berardi, A.C. 1973. Effect of cannabidiol and of other Cannabis sativa compounds on hippocampal seizure discharges. Psychopharmacologia, 28, 95–102.

  29. Jones, N.A., Glyn, S.E., Akiyama, S., Hill, TDM, Hill, A.J., Weston, S.E., Burnett, M.D.A., Yamasaki, Y., Stephens, G.J., Whalley, B.J., Williams, C.M. 2012. Cannabidiol exerts anticonvulsant effects in animal models of temporal lobe and partial seizures. Seizure, 21, 344–352.

  30. Klein, T.W. 2005. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews Immunology, 5, 400–411.

  31. Kowalski, C.W., Ragozzino, F.J., Jonathan, E.M., Lindberg, B.P., Lugo, J.M., McLaughlin, R.J. Peters, J.H. 2020. Cannabidiol activation of vagal afferent neurons requires TRPA1. Journal of Neurophysiology, 124, 1388–1398.

  32. Kumar, R.N., Chambers, W.A., Pertwee, R.G. 2001. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia, 56, 1059–1068.

  33. Leo, A., Russo, E., Elia, M. 2016. Cannabidiol and epilepsy: rationale and therapeutic potential. Pharmacological Research 107, 85–92.

  34. Lowin, T., Tingting, R., Zurmahr, J., Classen, T., Schneider, M., Pongratz, G. 2020. Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death & Disease, 11, 714.

  35. Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R., Feldmann, M. 2000. The non-psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences, 97, 9561.

  36. Martínez-Aguirre, C., Carmona-Cruz, F., Velasco, A.L., Velasco, F., Aguado-Carrillo, G., Cuéllar-Herrera, M., Rocha, L. 2020. Cannabidiol acts at 5-HT1A receptors in the human brain: relevance for treating temporal lobe epilepsy. Frontiers in Behavioral Neuroscience, 14.

  37. Masataka, N. 2019. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Frontiers in Psychology, 10.

  38. McGrath, S., Bartner, L.R., Rao, S., Packer, R.A., Gustafson, D.L. 2019. A randomized, blinded, controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. Journal of the American Veterinary Medical Association, 254, 1301–1308.

  39. Mechoulam, R. 1986. The pharmacohistory of Cannabis sativa. In: Mechoulam R (ed), The Cannabinoids as therapeutic agents. Chapman and Hall/CRC Press Inc., Boca Raton, FL, 1-20.

  40. Messina, F., Rosati, O., Curini, M., Marcotullio, M.C. 2015. Cannabis and bioactive cannabinoids. Studies in natural products chemistry, 45, 17–57.

  41. Moreira, F.A., Aguiar, D.C., Guimarães, F.S. 2006. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Progress in Neuropsychopharmacology & Biological Psychiatry, 30, 1466–1471.

  42. Muller, C., Morales, P., Reggio, P.H. 2018. Cannabinoid ligands targeting TRP channels. Frontiers in Molecular Neuroscience, 11, 487.

  43. Nardo, M., Casarotto, P.C., Gomes, F.V., Guimarães, F.S. 2014. Cannabidiol reverses the mCPP-induced increase in marble-burying behavior. Fundamental Clinical Pharmacology, 28, 544–550.

  44. O’Brien, K., Blair, P. 2021. Overview of medicinal cannabis. In medicinal cannabis and CBD in mental healthcare, 89–129. Cham: Springer International Publishing.

  45. Ohtsuki, T., Friesen, J.B., Chen, S.N., Mcalpine, J.B., Pauli, G.F. 2022. Selective preparation and high dynamic-range analysis of cannabinoids in “CBD Oil” and other Cannabis sativa preparations. Journal of Natural Products, 85, 634–646.

  46. Philpott, H.T., O’Brien, M., McDougall, J.J. 2017. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain, 158, 2442–2451.

  47. Pumroy, R.A., Samanta, A., Liu, Y., Hughes, T.E., Zhao, S., Yudin, Y., Rohacs, T., Han, S., Moiseenkova-Bell, V.Y. 2019. Molecular mechanism of TRPV2 channel modulation by cannabidiol. Elife, 8.

  48. Russo, E.B. 2008. Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management 4, 245–259.

  49. Sales, A.J., Fogaça, M.V., Sartim, A.G., Pereira, V.S., Wegener, G., Guimarães, F.S., Joca, S.R.L. 2019. Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex. Molecular Neurobiology, 56, 1070–1081.

  50. Sarfaraz, S., Adhami, V.M., Syed, D.N., Afaq, F., Mukhtar H. 2008. Cannabinoids for cancer treatment: progress and promise. Cancer Research, 68, 339–342.

  51. Solowij, N., Broyd, S.J., Beale, C., Prick, J.A., Greenwood, L.M., van Hell, H., Suo, C., Galettis, P., Pai, N., Fu, S., Croft, R.J., Martin, J.H., Yücel M. 2018. Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Research, 3, 21–34.

  52. Todd, S.M, Arnold J.C. 2016. Neural correlates of interactions between cannabidiol and Δ9-tetrahydrocannabinol in mice: implications for medical cannabis. British Journal of Pharmacology, 173, 53–65.

  53. Todd, S.M., Zhou, C., Clarke, D.J., Chohan, T.W., Bahceci, D., Arnold, J.C. 2017. Interactions between cannabidiol and Δ(9)-THC following acute and repeated dosing: rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway. European Neuropsychopharmacology, 27, 132–145.

  54. Vela, J., Dreyer, L., Petersen, K.K., Arendt-Nielsen, L., Duch, K. S., Kristensen, S. 2022. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain, 163, 1206–1214.

  55. Verrico, C.D., Wesson, S., Konduri, V., Hofferek, C.J., Vazquez-Perez, J., Blair, E., Dunner Jr, K., Salimpour, P., Decker, W.K., Halpert, M.W. 2020. A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain, 161, 2191–2202.

  56. Wade, D.T., Robson, P., House, H., Makela, P., Aram, J. 2003. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation, 17, 21–29.

  57. WHO. 2022. Mental Health. https://www.who.int/health-topics/mental-health#tab=tab_2.

  58. Wong, H., Cairns, B.E. 2019. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Archives of Oral Biology, 104, 33–39.

  59. Xu, C., Chang, T., Du, Y., Yu, C., Tan, X., Li, X. 2019. Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model. Environmental Toxicology and Pharmacology, 70, 103202.

  60. Zhao, P., Abood, M.E. 2013. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sciences, 92, 453–457.


ARTICLE INFORMATION

Received: 2022-05-25
Revised: 2022-08-22
Accepted: 2022-10-11
Available Online: 2022-10-28


Cite this article:

Özenver, N., Agrawal, D.C. Cannabidiol (CBD) for relief from pain, anxiety, and epilepsy: A review. International Journal of Applied Science and Engineering, 19, 2022115. https://doi.org/10.6703/IJASE.202212_19(4).006

  Copyright The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are cited.

Other people also read ...